ILCs can be replenished and complemented, albeit only in part, through contributions of hematogenously derived precursors or mature cells in situations of extended inflammation and tissue repair. Consistent with our findings, it has been reported that ILC subsets are elevated in the peripheral blood of patients suffering from psoriasis (30, 31) . Furthermore, peripheral blood ILC2s have been shown to dynamically modulate the expression of molecules that regulate tissue homing in mice and humans (20, 32) . In addition, we have detected donor-derived lymphoid and ILC progenitors in parabiotic BM ( fig. S8 ), raising the possibility that ILC progenitors can physiologically seed tissues not only during embryonic development (3) but also in adult mice. It remains to be determined whether this observation reflects the physiologic migration of ILC progenitors or the engraftment of donor-derived hematopoietic stem cells (33, 34) giving rise to ILCs. Independent of these considerations, our data support a model in which ILCs are locally maintained and expanded as tissue-resident cells during homeostasis and acute infection. This "sedentary" lifestyle of ILCs in broadly differing microenvironments is consistent with the proposed roles of ILCs as sentinels and local keepers of tissue function. Esther Peluso, 1 Daniel Metzger, 5 Hiroshi Ichinose, 6 Iftach Shaked, 1 Grzegorz Chodaczek, 4 Subhra K. Biswas, 7 Catherine C. Hedrick 1
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The immune system plays an important role in regulating tumor growth and metastasis. Classical monocytes promote tumorigenesis and cancer metastasis, but how nonclassical "patrolling" monocytes (PMo) interact with tumors is unknown. Here we show that PMo are enriched in the microvasculature of the lung and reduce tumor metastasis to lung in multiple mouse metastatic tumor models. Nr4a1-deficient mice, which specifically lack PMo, showed increased lung metastasis in vivo. Transfer of Nr4a1-proficient PMo into Nr4a1-deficient mice prevented tumor invasion in the lung. PMo established early interactions with metastasizing tumor cells, scavenged tumor material from the lung vasculature, and promoted natural killer cell recruitment and activation. Thus, PMo contribute to cancer immunosurveillance and may be targets for cancer immunotherapy.
M
onocytes and monocyte-derived macrophages play key roles in tumor progression (1-4). Classical "inflammatory" monocytes (CCR2 high Ly6C + in mice; CCR2 high CD14 + CD16 -in humans) are recruited to tumor sites where they contribute to macrophage content and promote growth and metastasis (5, 6) . In contrast, very little is known about the role of nonclassical "patrol-
+ in humans) in the early growth and metastasis of tumors. PMo are involved in the resolution of inflammation; they actively survey the endothelium of the vasculature, where they scavenge microparticles and remove cellular debris (7) (8) (9) . The orphan nuclear receptor Nr4a1 (also known as Nur77/TR3/NGIFB) is highly expressed in PMo compared with other immune cells and functions as a master regulator for the development of PMo in mice (10) .
To investigate the actions of PMo during early tumor metastasis, we used mice expressing green fluorescent protein (GFP) under the control of the Nr4a1 promoter (Nr4a1-GFP mice). In these mice, PMo (but not Ly6C + classical monocytes) express high levels of GFP (GFP high ) (10, 11). We focused our studies on the lung, which is a common site of tumor metastasis and an important locus of PMo activity (12) (13) (14) . We used flow cytometry to confirm that Nr4a1-GFP high cells in the lung were PMo ( fig. S1 , A to C). Tracking of Nr4a1-GFP high cells by confocal imaging in the lungs allowed us to identify a large number of Nr4a1-GFP high PMo patrolling the microvasculature (movie S1 and Fig. 1A ). Consistent with an important role for PMo in the lung vasculature, we found a three-to fourfold enrichment of Nr4a1-GFP high PMo in the lung compared with other tissues (fig. S1D) .
To examine the interactions of PMo with tumors in vivo, we imaged Nr4a1-GFP high PMo in the lung after intravenous (IV) injection of Lewis lung carcinoma cells expressing red fluorescent protein (LLC-RFP). The number of Nr4a1-GFP high monocytes in the lung increased significantly 24 hours after injection, which implies that PMo are actively recruited to the lung tumor environment (Fig. 1A) . Within 4 hours after tumor injection, most Nr4a1-GFP high monocytes exhibited decreased patrolling speed in the vasculature, and by 24 hours they had arrested near lung tumor sites (Fig. 1B) . The majority of Nr4a1-GFP high monocytes isolated from the lung after LLC tumor transfer maintained their PMo phenotype, which we further confirmed in vitro (Fig.  1C and fig. S1 ).
Nr4a1-GFP high PMo were recruited to tumor cell clusters within 30 min after IV tumor injection, and recruitment continued for at least 7 days (Fig. 1, D Nr4a1-GFP high monocytes patrolling the vasculature 4 hours after tumor injection appeared to move toward and inhibit the attachment of tumor cells to the lung microvasculature (movie S3). We examined whether Nr4a1-GFP high PMo could extravasate outside the vasculature. We found that by 4 hours after tumor injection, 10 to 20% of Nr4a1-GFP high PMo had extravasated at tumor sites ( fig. S2 , B and C), and this increased to 40 to 50% PMo extravasation by 7 days. Together, these findings confirm that PMo establish early immune interactions with tumor cells and can extravasate and accumulate at tumor sites.
To determine whether PMo have a major role in regulating tumor invasion, metastasis, and growth in the lungs in vivo, we used Nr4a1 knockout (Nr4a1 −/− ) mice, which exhibit selective loss of PMo (10) 
(fig. S3). Nr4a1
−/− mice were IV injected with either syngeneic B16F10 melanoma cells expressing a luciferase reporter or LLC-RFP cells (Fig. 2 , A and B, and figs. S4 and S5). As early as 24 hours and up to 21 days after IV injection of B16F10 melanoma, we observed increased tumor invasion in the lungs of Nr4a1 −/− mice compared with control mice (Fig. 2, A and B, and fig. S4, A and B). We observed no differences in either Ly6C + monocyte or Ly6G + granulocyte populations in the lungs of these mice 7 days after tumor injection ( fig. S4C ). B16F10 tumor invasion appeared to be specific for the lung, as increased tumor metastasis was not observed in the liver ( fig S4B) . Additionally, increased spontaneous metastases to the lung were observed in Nr4a1 −/− mice after subcutaneous injection of B16F10 melanoma, which suggests that Nr4a1 expression is important for suppressing primary tumor metastasis to the lung (Fig. 2C) . A similar early and sustained increase in lung metastasis in Nr4a1 −/− mice was also observed after intravenous LLC tumor transfer ( fig. S5 ). We did not detect differences in lung vascular permeability between Nr4a1 −/− and control mice ( fig. S6 ).
We next investigated the mouse mammary tumor virus-polyoma middle T (MMTV-PyMT) model, in which female mice spontaneously develop mammary tumors that metastasize to the lung (15 transplants using either wild-type (WT) or Nr4a1 −/− bone marrow transferred into female recipient MMTV-PyMT mice. MMTV-PyMT mice receiving Nr4a1 −/− bone marrow developed significantly higher numbers of spontaneous metastases to the lung but no differences in primary mammary tumor growth compared to mice receiving WT bone marrow (Fig. 2, D and E) .
We further tested hematopoietic Nr4a1 function using B16F10 melanoma. Only mice receiving Nr4a1 −/− bone marrow had increased B16F10 tumor metastases, confirming that Nr4a1 expression in hematopoietic cells regulated tumor cell metastasis to the lung (fig. S7, A and B) . Analysis of immune cells isolated from lung tumors verified a selective loss of PMo in Nr4a1 −/− bone marrowtransplanted mice ( fig. S7C ). In the 1:1 chimera mice, we observed equal reconstitution of immune cells from each donor (fig. S7D ). However, PMo were derived almost exclusively from WT bone marrow, suggesting that the restoration of the Ly6C
− monocyte population prevented tumor metastasis.
To confirm that Nr4a1 expressed in myeloid cells was regulating tumor metastasis to the lung, we examined two different myeloid-specific Nr4a1 conditional knockout models (CSF1R-Cre 
Nr4a1
fl/fl mice significantly reduced the number of PMo in circulation ( fig. S8 ) and increased tumor lung metastasis (Fig. 3, A and B, and fig. S9 ). Nr4a1 deletion using CSF1R-Cre or LysM-Cre also targets Nr4a1 in macrophages and Ly6C + monocytes, so we cannot completely rule out effects of Nr4a1 in these cells. However, Nr4a1 expression in macrophages and Ly6C + monocytes is relatively low, which suggests limited Nr4a1 function (10, 16, 17) . No differences in tumor metastasis were observed with T lymphocyte-specific Nr4a1 deletion ( fig. S10) . Collectively, our studies illustrate increased lung metastasis burden in the absence of Nr4a1 in myeloid cells in multiple cancer models.
To confirm a direct role for PMo in regulating tumor metastasis, WT Ly6C + or Ly6C − monocytes were adoptively transferred into recipient Nr4a1 −/− mice before tumor injection. A substantial number of the transferred monocytes could be found in the lungs (fig. S11, A and B) . Reconstitution of PMo into Nr4a1 −/− mice prevented lung tumor metastasis (Fig. 3, C and D) . In contrast, transfer of Ly6C + monocytes into Nr4a1 −/− mice actually promoted tumor metastasis, consistent with known protumoral properties of this subset of monocytes (5, 18). The majority (80 to 90%) of transferred Ly6C + monocytes in circulation did not lose Ly6C expression ( fig. S11C) . Transfer of PMo 24 hours after tumor injection into Nr4a1 −/− mice did not suppress tumor metastasis ( fig. S11D ), suggesting that PMo must already be present and active in the vasculature to prevent early tumor metastasis. These data directly show that nonclassical PMo inhibit tumor metastasis to the lung.
Patrolling monocytes can act as "intravascular housekeepers" that scavenge microparticles and remove cellular debris from the microvasculature (7). Extracellular vesicles from tumors are important mediators of tumor metastasis, progression, and immune suppression, and targeting their removal is an emerging focus for cancer therapy (19, 20) . We used high-resolution confocal imaging to determine whether PMo could engulf and remove tumor material from the lung vasculature. A sizable number of Nr4a1-GFP high PMo containing large amounts of LLC-RFP tumor material were observed at tumor sites in the lung 24 hours after IV tumor transfer (Fig. 3E) . Coculture assays of mouse PMo with fluorescently labeled tumor cells confirmed engulfment of large amounts of tumor material (Fig. 3F) . Analysis of monocyte populations isolated from the lung at 24 hours after IV LLC-RFP injection indicated that PMo preferentially took up~fivefold more tumor material than did Ly6C monocytes (Fig. 3G) . PMo also preferentially took up substantially more B16F10-yellow fluorescent protein (YFP) tumor material, with an average tumor material size of 1.39 mm 2 and an average total amount of tumor material per monocyte of 1.92 mm 2 ( fig. S12, A and B) . The homologous human CD14 dim CD16 + population of PMo, which similarly has high Nr4a1 expression (8, 21) , also engulfed a large quantity of tumor material in vitro, suggesting analogous tumor engulfment function ( fig. S12C) . Moreover, PMo actively engulfed tumor material within classic endocytic compartments (22) (Fig. 4A) . Collectively, these results demonstrate that Nr4a1-dependent PMo rapidly and preferentially endocytose tumor material.
We then asked how PMo recognized tumor cells to prevent metastasis in the lung. The chemokine receptor CX3CR1 is highly expressed on PMo and is important for their arrest at inflammatory sites ( fig. S13A) (23-25) . CX3CR1-deficient(Cx3cr1 −/− ) mice, which also have a significant reduction in PMo, exhibit a similar phenotype to Nr4a1 −/− mice (i.e., increased tumor burden and metastasis to the lung) (26, 27) . Although PMo numbers were reduced in the lung vasculature of Cx3cr1 −/− mice [~30 to 50% reduction ( fig. S13B ), confirming previous reports] (27), a major proportion of the remaining CX3CR1-deficient PMo was observed patrolling the vasculature, as previously observed (7) . Unlike Cx3cr1
−/− PMo did not arrest near LLC tumor cells and instead remained patrolling within the lung vasculature (Fig. 4, B and C, and movie S6). Cx3cr1 −/− PMo were not recruited to the lung 24 hours after LLC tumor challenge, whereas Ly6C + recruitment was unaffected by the loss of CX3CR1 expression ( fig.  S13B ). Cx3cr1 −/− PMo present in the lung showed defective engulfment of tumor material, indicating that CX3CR1 expression on PMo is critical for mediating the sensing and uptake of tumor material (Fig. 4D ). CX3CL1, a ligand for CX3CR1, has been reported to be present in high levels in human and mouse lungs (28) . Using a CX3CL1-mCherry reporter mouse (29), we found that CX3CL1 was specifically expressed on CD31 + endothelial cells (ECs) at low levels in the lung microvasculature (Fig. 4, E and F, and fig. S13C ). CX3CL1 expression was most prevalent in lung ECs compared with ECs in other tissues ( fig. S13D) , which may partially explain the enrichment and preferential function of PMo in the lung. CX3CL1 expression on lung ECs increased in response to tumor challenge (Fig. 4E) and at sites of tumor metastasis (Fig. 4F) , consistent with reports of increased CX3CL1 during lung inflammation (30) . Toll-like receptor 7 (TLR7) has been linked to recruitment of PMo in response to kidney damage in mice (7) . However, we found that TLR7 did not play a major role in either recruitment of PMo to the lung after tumor injection ( fig. S13B ) or uptake of tumor material by PMo (Fig. 4D) . We conclude that both CX3CR1 expression on monocytes and CX3CL1 expression by ECs are critical for recruitment of PMo to sites of tumor extravasation to mediate the removal of tumor material from the lung. CX3CL1 expression by tumor cells (31) may also drive monocyte recruitment. In agreement with our findings, many studies have reported that CX3CL1 expression by either tumor cells or tumor-associated cells is antitumoral and correlated with good prognosis (32) (33) (34) . However, the function of the CX3CL1/ CX3CR1 axis, particularly during later stages of tumor growth, is complex (35, 36) .
Finally, we examined whether PMo can directly kill tumor cells. After multiple attempts using various experimental conditions, direct killing of tumor cells by PMo was not observed (fig. S14 ). However, PMo may be important for antibodydependent cell-mediated cytotoxicity of either tumor cells or suppressive immune cells within the tumor environment (37, 38) . In response to IVinjected B16F10 tumor, PMo isolated from lungs produced significantly higher levels of natural killer (NK) cell activation and recruitment-related chemokines CCL3, CCL4, and CCL5, as compared with classical Ly6C + monocytes (Fig. 4G) (39, 40) . In accord with this finding, myeloid-specific Nr4a1 knockout mice (CSF1R-Cre +
fl/fl ) showed reduced NK cell recruitment to the lung in response to tumor (Fig. 4H) , suggesting that PMo controlled the recruitment of NK cells to tumor sites. A similar reduction in NK cell recruitment and CD44 activation ( fig. S15, A and B) was also observed in the lungs of PyMT mice that received Nr4a1-deficient bone marrow. However, Nr4a1 does not regulate NK cell development ( fig. S15C) . Uptake of tumor material by PMo does not require the presence of NK cells (fig. S16, A and B) . NK cell depletion reduced the differences in . S16C) . Thus, PMo inhibit metastasis, at least in part, through the regulation of NK cell recruitment and activity.
In summary, we demonstrate that PMo participate in cancer surveillance by preventing tumor metastasis to lung. PMo are actively recruited to lung metastasis sites in a CX3CR1-dependent manner, where they function to scavenge tumor material, as well as to recruit and activate NK cells, leading to the prevention of tumor cell metastasis ( fig. S17) . Selective targeting by increasing PMo activity and/or their regulation by Nr4a1 may represent a novel therapy for the prevention of cancer metastasis to the lung.
